June 29, 2026 06:19 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
India overtakes Taiwan, South Korea to become world's fifth-largest equity market again | Pakistan strikes terror hideouts near Afghan border after Karachi bloodshed, 29 killed | Israel strikes back: Top October 7 militant “eliminated” in precision operation | Radharaman Das, who defended Bengal's vegetarian mid-day meal plan, loses ISKCON post | Fresh paper leak rocks India: Maharashtra TET postponed a day before exam, over 4 lakh aspirants affected | Pune fort murder case: Siya Goyal's brother says family would have called off marriage if she had objected | Donald Trump gets a road named after him in India, says 'Thank You!' | Fresh setback for Gautam Adani? US judge asks DoJ to justify dropping criminal charges | Ram Mandir Trust chief Champat Rai resigns as alleged donation siphoning row escalates | Ram Mandir fund row deepens: 8 arrested days after BJP called allegations 'false narrative'
Johnson Baby Powder
Image Credit: wikipedia.org

Maharashtra FDA cancels Johnson & Johnson baby powder licence

| @indiablooms | Sep 18, 2022, at 05:06 am

Mumbai: The Maharashtra FDA has cancelled the baby talcum powder manufacturing licence of Johnson & Johnson, Mulund, after the department found it "Not Of Standard Quality".

The FDA said that the licence was cancelled after samples of the Johnson’s Baby Powder collected from Nashik and Pune failed quality checks and ordered the company to recall all its stocks from the markets.

These samples were declared by the FDA as ‘Not Of Standard Quality’ after they failed to comply with IS5339:2009 (Second Revision Amendment No. 3) Specification for Skin Powder for infants in the test pH.

In a statement, the FDA said: “The product Johnsons Baby Powder is popularly used in newborn babies. The sample declared 'Not of Standard' in pH and the use of the product may affect the health of the skin of the newborn babies.”

The firm "didn't accept the report" and challenged it in court for sending it to the Central Drugs Laboratory, the FDA said, according to media reports.

(With UNI inputs)

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.